Organic Active Ingredients TRIZ Cases

A foam aerosol with lipophilic enhancers improves minoxidil skin permeation while preventing scalp run-off during hair loss treatment.

A solid dispersion of Compound I with copovidone and crystalline sofosbuvir improves bioavailability while reducing food-effect and dosing variability.

A novel CRBN ligand scaffold enables PROTAC formation with high activation rates while reducing neutropenia, thrombocytopenia, and neuropathy.

Quinazolin-8-yl derivatives inhibit EGFR kinase, helping treat EGFR-mutant cancers by modulating cellular proliferation and differentiation.

A 5-40 μL coated valve cuts propellant release and albuterol sticking, improving dose consistency in a smaller inhaler.

Twice-daily PDE4B inhibitor plus pirfenidone or nintedanib slows PF-ILD progression while reducing gastrointestinal adverse events.

HLSC-derived extracellular vesicles deliver miR222 to suppress miR21, TGFβ, and collagen production in hyperglycemia-driven renal fibrosis.

Segmented azaketolide synthesis cuts macrolide route complexity while retaining potent activity against resistant Gram-negative bacteria.

Blocking the C5aR1 complement pathway helps prevent or treat taxane hypersensitivity reactions that persist despite standard premedication.

Controlled mismatches, bulges, and loops shape an ADAR editing substrate that improves target RNA editing efficiency and specificity.

Citrate-to-Tris buffer exchange helps nucleic acid lipid nanoparticles balance delivery efficiency, storage stability, and lower cytotoxicity.

A wax-polymer-sugar zonisamide formulation delivers pseudo zero-order release within short animal GI transit, avoiding burst release and poor bioavailability.

WRN helicase inhibition exploits dMMR synthetic lethality to trigger DNA breaks and apoptosis in MSI-H tumors with resistance to current therapies.

Continuous NO release combined with PDE4 inhibition improves microcirculation, reduces inflammation, and broadens ARDS treatment.

Modified dsRNA and lipid carriers suppress CIDEB mRNA while improving in vivo delivery and stability for NAFLD and NASH treatment.

Selective pyrimidine EGFR inhibitors broaden treatment coverage to exon 20 insertions while improving safety and activity against resistant mutants.

Segmented heterocyclic scaffold tuning improves AAK1 inhibition while preserving compound diversity for CNS disease drug discovery.

Controlled benzoate dosing reduces microglia activation and neuroinflammation to improve long COVID brain fog without adverse side effects.

A macrocyclic compound targets the TYK2 JH2 domain to improve selectivity over JAK family members while enabling blood-brain barrier penetration.

Defined spiro compound crystal forms use XRPD fingerprints to improve stability, factor D inhibition, and oral bioavailability.

Specific tetracycline analogs improve mPTP-opening inhibition while addressing the limits of cyclosporine A in physicochemical properties and therapy.

Novel dispiropyrrolidine derivatives block Mdm2-p53 binding to restore p53 activity and suppress cancer cell proliferation.

Combining an anxiolytic with a stimulant helps treat PTSD and HSDD while simplifying administration and sustaining symptom relief.

PPEF2 genotyping guides iloperidone selection and dosing to reduce schizophrenia treatment trial and error and improve symptom control.

Tie-2 activation via HPTPβ/VE-PTP inhibition helps reduce vascular leak, inflammation, and edema while improving lung oxygenation in ARDS.

An elastic linear member lets the gastrostomy catheter bumper deform for easier insertion while maintaining stable long-term placement.

Cas13b guide RNA delivered by AAV silences DUX4 RNA to reduce muscle toxicity and support cell survival in FSHD.

Targeting coronavirus papain-like protease with YM155, tanshinone I, and cryptotanshinone enables antiviral activity with low cytotoxicity.

A multi-gene expression signature improves recurrence risk prediction in early-stage breast cancer, helping avoid overtreatment and toxicity.

Targeted dsRNA silences ANGPTL3 expression to lower serum lipids and address inconsistent response to conventional lipid therapies.

Combining a CB1 antagonist with everolimus helps suppress neuroendocrine tumor growth while preventing resistance pathways in metastatic NENs.

Synthetic apoptosis-mimicking scaffold structures recruit macrophages and endogenous stem cells to regenerate bone without cell seeding.

Reversible copper-ligand self-assembly controls degradation and maintains copper ion release over 1 to 30 days for antimicrobial use.

Simplified acyl hydrazide linkers preserve nanomolar LecA binding while improving synthesis and drug-like properties for blocking P. aeruginosa biofilms.

Crystalline forms of a TYK2 inhibitor improve selectivity, potency, and pharmacokinetic behavior for autoimmune disease treatment.

Combining an EP4 antagonist with immune checkpoint inhibitors blocks PGE2-driven immune suppression and improves antitumor response.

Converting psilocin into pharmaceutically acceptable salts improves crystallinity, purity, oxidation stability, and water solubility.

Amorphous solid dispersions with polymers raise PARP inhibitor dissolution and oral bioavailability while limiting crystalline content.

A polymer-based dasatinib amorphous solid dispersion maintains delivery despite elevated gastric pH and acid-reducing agents.

Targeting VDAC1 blocks mtDNA release to curb IBD inflammation while avoiding the broad immune suppression seen with current treatments.

Superparamagnetic neutrophil-mimetic vesicles improve tumor targeting, reduce harm to normal cells, and enhance anticancer drug delivery.

A biodegradable subcutaneous implant releases hydrocortisone continuously to restore circadian cortisol levels and avoid frequent dosing.

A SERM and pregnenolone combination raises testosterone while maintaining LH and FSH to preserve testicular function and fertility.

Specific bupropion and dextromethorphan dosing helps treat depression and Alzheimer's agitation while limiting QT prolongation and dissociation.

Specific polymorphs of an EGFR inhibitor improve brain penetrance and stability, addressing glioblastoma resistance and delivery limits.

Twice-weekly intravenous brincidofovir dosing defines a clearer regimen to cut adenovirus viral load faster and reduce treatment failure.

Structural changes to itraconazole reduce CYP3A4 inhibition while preserving anti-angiogenic and Hedgehog pathway activity for cancer treatment.

Local pazopanib delivery raises neutrophil ROS to reduce lung permeability, edema, and mortality in acute lung injury.

Electrophilic thiophene derivatives selectively covalently bind KRAS G12C to improve antiproliferative activity while limiting off-target toxicity.

C4-modified oleanolic acid derivatives selectively reduce IL-17 levels to improve autoimmune disease treatment with fewer side effects.